Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $660.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective hoisted by Scotiabank from $558.00 to $660.00 in a report published on Tuesday morning,Benzinga reports. The firm currently has a sector outperform rating on the pharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Daiwa Securities Group upped their price objective on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Morgan Stanley reduced their price target on Vertex Pharmaceuticals from $665.00 to $660.00 and set an “overweight” rating on the stock in a research report on Tuesday. Jefferies Financial Group upped their price objective on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. Cantor Fitzgerald raised their price target on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Canaccord Genuity Group boosted their price objective on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $596.44.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $542.50 on Tuesday. Vertex Pharmaceuticals has a 12-month low of $406.67 and a 12-month high of $568.67. The company has a current ratio of 2.34, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average of $522.81 and a two-hundred day moving average of $481.42. The stock has a market cap of $137.69 billion, a P/E ratio of 34.91, a PEG ratio of 2.84 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The company had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.80 EPS. As a group, research analysts predict that Vertex Pharmaceuticals will post 16.50 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Maryland State Retirement & Pension System increased its stake in Vertex Pharmaceuticals by 14.2% during the 3rd quarter. Maryland State Retirement & Pension System now owns 15,568 shares of the pharmaceutical company’s stock valued at $8,139,000 after buying an additional 1,941 shares during the period. Ritholtz Wealth Management raised its holdings in shares of Vertex Pharmaceuticals by 5.0% during the third quarter. Ritholtz Wealth Management now owns 4,943 shares of the pharmaceutical company’s stock valued at $2,584,000 after acquiring an additional 234 shares during the period. UNIVEST FINANCIAL Corp raised its stake in Vertex Pharmaceuticals by 140.7% during the 3rd quarter. UNIVEST FINANCIAL Corp now owns 21,785 shares of the pharmaceutical company’s stock valued at $11,389,000 after purchasing an additional 12,736 shares during the period. Joel Isaacson & Co. LLC raised its position in Vertex Pharmaceuticals by 6.8% during the third quarter. Joel Isaacson & Co. LLC now owns 614 shares of the pharmaceutical company’s stock valued at $321,000 after buying an additional 39 shares during the period. Finally, Jacobi Capital Management LLC increased its stake in Vertex Pharmaceuticals by 16.2% in the 3rd quarter. Jacobi Capital Management LLC now owns 1,318 shares of the pharmaceutical company’s stock valued at $689,000 after buying an additional 184 shares during the period. Institutional investors own 90.96% of the company’s stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.